To the best of our knowledge, this is the first study showing that PCSK9 can predict worse clinical cardiovascular outcomes in diabetic patients with stable CAD and the combination of plasma PCSK9 levels and diabetes status enhanced predictive value in CAD patients. This evidence concerns the gene PCSK9 and diabetes mellitus.